Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cypress Bioscience gets antipsychotic compound from BioLineRx; deal terminated

Executive Summary

Cypress Bioscience Inc. (CNS therapies and personalized diagnostics) has licensed exclusive development and commercialization rights in the US, Canada, and Mexico to Israeli drug company BioLineRx Ltd.'s BL1020 (renamed CYP1020) for schizophrenia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal

Related Companies